Evidence Repository - Clinical Genome Resources

The ClinGen Evidence Repository is an FDA-recognized human genetic variant database containing expert-curated assertions regarding variants' pathogenicity and supporting evidence summaries. [Disclaimer]

Variant: NM_001754.5(RUNX1):c.*3642C>T

Curation Version - 1.0
Curation History
JSON LD for Version 1.0

CA1139666828

897093 (ClinVar)

Gene: RUNX1

Condition: hereditary thrombocytopenia and hematologic cancer predisposition syndrome

Inheritance Mode: Autosomal dominant inheritance

Link to MONDO

UUID: 139d0994-4b3d-40cf-8ec7-22368f728c97

Approved on: 2024-11-13

Published on: 2024-11-13

HGVS expressions

NM_001754.5:c.*3642C>T

NM_001754.5(RUNX1):c.*3642C>T

NC_000021.9:g.34788493G>A

CM000683.2:g.34788493G>A

NC_000021.8:g.36160790G>A

CM000683.1:g.36160790G>A

NC_000021.7:g.35082660G>A

NG_011402.2:g.1201219C>T

ENST00000675419.1:c.*3642C>T

ENST00000300305.7:c.*3642C>T

ENST00000344691.8:c.*3642C>T

ENST00000437180.5:c.*3642C>T

NM_001001890.2:c.*3642C>T

NM_001754.4:c.*3642C>T

NM_001001890.3:c.*3642C>T

Uncertain Significance

BS2 BS4 BS3 BS1 BP2 BP3 BP4 BP1 BP5 BP7 PS2 PS4 PS3 PS1 BA1 PP4 PP1 PP3 PP2 PM3 PM1 PM4 PM5 PM6 PM2 PVS1

Evidence Links 0

Expert Panel

Myeloid Malignancy VCEP

Criteria Specification Information

Criteria Specification: ClinGen Myeloid Malignancy Expert Panel Specifications to the ACMG/AMP Variant Interpretation Guidelines Version 2

PDF

Criteria Specification Approval History

Criteria Specifications for this VCEP

Evidence submitted by expert panel

Myeloid Malignancy VCEP

The NM_001754.5(RUNX1):c.*3642C>T is a 3'UTR variant which does not meet any ACMG/AMP criteria. In summary, the clinical significance of this variant is uncertain. ACMG/AMP criteria applied, as specified by the Myeloid Malignancy Variant Curation Expert Panel for RUNX1: None.

BS2

This rule is not applicable for MM-VCEP

BS4

Segregation data for this variant has not been reported in literature.

BS3

In vitro or in vivo functional data has not been reported for this variant in the literature.

BS1

This variant does not have a MAF between 0.00015 (0.015%) and 0.0015 (0.15%) in any general continental dataset.

BP2

This variant has not been observed in trans with a pathogenic variant for a fully penetrant dominant gene/disorder or observed in cis with a pathogenic variant in any inheritance pattern.

BP3

This rule is not applicable for MM-VCEP

BP4

This variant does not have applicable in-silico data available.

BP1

This rule is not applicable for MM-VCEP

BP5

This rule is not applicable for MM-VCEP

BP7

This variant is not a synonymous or intronic variant.

PS2

De novo data for this variant has not been reported in literature.

PS4

Proband data for this variant has not been reported in literature.

PS3

In vitro or in vivo functional data has not been reported for this variant in the literature.

PS1

This variant is not a missense variant.

BA1

This variant does not have a MAF ≥ 0.0015 (0.15%) in any general continental population dataset.

PP4

This rule is not applicable for MM-VCEP

PP1

Segregation data for this variant has not been reported in literature.

PP3

This variant does not have applicable in-silico data available.

PP2

This rule is not applicable for MM-VCEP

PM3

This rule is not applicable for MM-VCEP

PM1

This variant is not a missense variant.

PM4

This variant is not an in-frame deletion/insertion.

PM5

This variant is not a missense variant.

PM6

De novo data for this variant has not been reported in literature.

PM2

This variant is present in at least one population database (gnomAD 4.1 exomes - although with low coverage).

PVS1

This variant is not a null variant.

Curation History

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. If you have questions about the information contained on this website, please see a health care professional.